« Return to News | Clinical Intelligence

Northwest Bio gets OK for phase III brain cancer trial in the U.K.

Friday, August 24, 2012 09:00 AM

Northwest Biotherapeutics, a Bethesda, Md.-based biotech, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the U.K. to proceed with the company's 300-patient phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM).

The phase III clinical trial is already under way in the U.S., at 41 sites across the country. NW Bio is now expanding the study to make it an international trial, by including clinical trial sites in Europe. This international approach can potentially save years of time in clinical trials, compared with conducting trials in the U.S. and Europe separately.

NW Bio's submission of the phase III trial application to the MHRA, as well as the MHRA's acceptance of the trial's designation as a phase III trial and rapid approval of the trial, mark the culmination of two years of preparatory work and foundation-building in the U.K.

"We are excited and very grateful to the MHRA for its rapid approval, allowing our GBM brain cancer trial to proceed as a phase III trial in the U.K. as an expansion of the ongoing phase III trial in the U.S," said Linda Powers, CEO of NW Bio. "There is an urgent medical need for better treatment options for GBM, the most lethal form of brain cancer. We appreciate the opportunity to efficiently include the U.K. in our ongoing phase III trial, so that we can bring the DCVax-L immune therapy to patients in the U.K. as well as the U.S."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.